Repositorio Institucional
Repositorio Institucional
CONICET Digital
  • Inicio
  • EXPLORAR
    • AUTORES
    • DISCIPLINAS
    • COMUNIDADES
  • Estadísticas
  • Novedades
    • Noticias
    • Boletines
  • Ayuda
    • General
    • Datos de investigación
  • Acerca de
    • CONICET Digital
    • Equipo
    • Red Federal
  • Contacto
JavaScript is disabled for your browser. Some features of this site may not work without it.
  • INFORMACIÓN GENERAL
  • RESUMEN
  • ESTADISTICAS
 
Artículo

Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients before bone osteolytic metastasis

Fernández Vallone, Valeria BeatrizIcon ; Hofer, Erica L.; Choi, Hosoon; Bordenave, Raúl H.; Batagelj, Emilio; Feldman, Leonardo; La Russa, Vincent; Caramutti, Daniela; Dimase, Federico; Labovsky, VivianIcon ; Martinez, Leandro MarceloIcon ; Chasseing, Norma AlejandraIcon
Fecha de publicación: 01/03/2013
Editorial: Springer
Revista: Clinical & Experimental Metastasis
ISSN: 1573-7276
e-ISSN: 1573-7276
Idioma: Inglés
Tipo de recurso: Artículo publicado
Clasificación temática:
Medicina Química; Oncología

Resumen

Tumour cells can find in bone marrow (BM) a niche rich in growth factors and cytokines that promote their self-renewal, proliferation and survival. In turn, tumour cells affect the homeostasis of the BM and bone, as well as the balance among haematopoiesis, osteogenesis, osteoclastogenesis and bone-resorption. As a result, growth and survival factors normally sequestered in the bone matrix are released, favouring tumour development. Mesenchymal stem cells (MSCs) from BM can become tumour-associated fibroblasts, have immunosuppressive function, and facilitate metastasis by epithelial-to-mesenchymal transition. Moreover, MSCs generate osteoblasts and osteocytes and regulate osteoclastogenesis. Therefore, MSCs can play an important pro-tumorigenic role in the formation of a microenvironment that promotes BM and bone metastasis. In this study we showed that BM MSCs from untreated advanced breast and lung cancer patients, without bone metastasis, had low osteogenic and adipogenic differentiation capacity compared to that of healthy volunteers. In contrast, chondrogenic differentiation was increased. Moreover, MSCs from patients had lower expression of CD146. Finally, our data showed higher levels of Dkk-1 in peripheral blood plasma from patients compared with healthy volunteers. Because no patient had any bone disorder by the time of the study we propose that the primary tumour altered the plasticity of MSCs. As over 70 % of advanced breast cancer patients and 30–40 % of lung cancer patients will develop osteolytic bone metastasis for which there is no total cure, our findings could possibly be used as predictive tools indicating the first signs of future bone disease. In addition, as the MSCs present in the BM of these patients may not be able to regenerate bone after the tumour cells invasion into BM/bone, it is possible that they promote the cycle between tumour cell growth and bone destruction.
Palabras clave: Celulas Madre Mesenquimales , Osteogenesis , Cancer de Mama , Metastasis Osea , Medicina Regenerativa , Bone Marrow
Ver el registro completo
 
Archivos asociados
Tamaño: 1.022Mb
Formato: PDF
.
Solicitar
Licencia
info:eu-repo/semantics/restrictedAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/5777
DOI: http://dx.doi.org/ 10.1007/s10585-012-9539-4
DOI: http://dx.doi.org/10.1007/s10585-012-9539-4
URL: http://link.springer.com/article/10.1007%2Fs10585-012-9539-4
Colecciones
Articulos(IBYME)
Articulos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Citación
Fernández Vallone, Valeria Beatriz; Hofer, Erica L.; Choi, Hosoon; Bordenave, Raúl H.; Batagelj, Emilio; et al.; Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients before bone osteolytic metastasis; Springer; Clinical & Experimental Metastasis; 30; 3; 1-3-2013; 317-332
Compartir
Altmétricas
 

Enviar por e-mail
Separar cada destinatario (hasta 5) con punto y coma.
  • Facebook
  • X Conicet Digital
  • Instagram
  • YouTube
  • Sound Cloud
  • LinkedIn

Los contenidos del CONICET están licenciados bajo Creative Commons Reconocimiento 2.5 Argentina License

https://www.conicet.gov.ar/ - CONICET

Inicio

Explorar

  • Autores
  • Disciplinas
  • Comunidades

Estadísticas

Novedades

  • Noticias
  • Boletines

Ayuda

Acerca de

  • CONICET Digital
  • Equipo
  • Red Federal

Contacto

Godoy Cruz 2290 (C1425FQB) CABA – República Argentina – Tel: +5411 4899-5400 repositorio@conicet.gov.ar
TÉRMINOS Y CONDICIONES